4.2.5 Emerging therapies
4.2.5 Emerging therapies
The key principle for precision medicine is prompt and clinically oriented communication and coordination with an accredited laboratory and pathologist. Tissue analysis is integral for access to emerging therapies and, as such, tissue specimens should be treated carefully to enable additional histopathological or molecular diagnostic tests in certain scenarios.
There is an increasing role for molecular pathology including RAS status, BRAF status and MSI status, which will influence treatment options.
MMR testing should be done routinely on all primary tumours. Methylation testing for tumours showing MLH1 loss should be undertaken if available. Methylation effectively excludes lynch syndrome.
For metastatic disease, molecular pathology is important including RAS status, BRAF status and MMR.